Lilly cited for"misleading" Cymbalta ads
While Eli Lilly's CEO was out lobbying for drug safety, the FDA was posting a letter on its website warning the drug maker to stop making "false and misleading" claims about its antidepressant Cymbalta.
At issue was a promotional mailing that left out some of the drug's most serious side effects and exaggerated its effectiveness at easing pain. (In addition to its approval for use in depression and anxiety, Cymbalta is approved for diabetic nerve pain.) The agency ordered Lilly to stop distributing the mailer--which was first used in 2005.
- check out the warning letter from the FDA
Related Article:
Lilly pursues new Cymbalta approval. Report
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends